Top LSK-specific signatures include normal embryonic stem cell related programs, hematopoietic stem cells and progenitors programs, while MSI2 controlled pathways and MLL-AF9 AML leukemia are amongst the most enriched signatures in LSC-specific targets (Fig. 3h, i, Supplementary Data 3). This evidence concerns the gene KMT2A and acute myeloid leukemia.